ADT-Induced Bone Loss: A Growing Problem

The impact of prostate cancer and the threat of impaired bone health

ADT: Decreasing BMD and Increasing Fracture Risk

Fractures are approximately 50% more likely in men treated with ADT versus those not receiving ADT

Impact of ADT-Induced Bone Loss

ADT increases risk of skeletal complications including fracture and pain, which can be costly and can impact activities of daily living

Cancer Treatment-Induced Bone Loss and Prostate Cancer

Prostate Cancer and ADT-Induced Bone Loss

In men, prostate cancer is the most commonly diagnosed cancer and accounts for a quarter of all new cancer cases in men.¹

Androgen deprivation therapy (ADT) has been shown to improve survival in patients with prostate cancer. As a result, patients will be treated chronically with ADT, putting them at increased risk for bone loss and fracture. Fractures have been associated with serious clinical and economic consequences.^2-4

References:

Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol. 2004;46:731-740.
Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS. Health care cost associated with prostate cancer androgen deprivation therapy and bone complications. J Urol. 2007;178:1423-1428.
Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-164